Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05877599 · ClinicalTrials.gov registry record · Phase 1
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 18
- Study locations
NCT05877599: Recruiting Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
NCT05877599 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 46 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05877599, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 18
- Study locations
Study Summary
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Primary Outcome
Incidence of dose-limiting toxicities (DLTs) after the infusion of NT-175
Conditions Studied
Interventions
- BIOLOGICAL Autologous, engineered T Cells targeting TP53 R175H
Study Locations (18)
California
- Research Site - Duarte
- Research Site - Newport Beach
- Research Site - Santa Monica
Florida
- Research Site - Jacksonville
- Research Site - Miami
- Research Site - Tampa
North Carolina
- Research Site - Charlotte
- Research Site - Winston-Salem
Texas
- Research Site - Houston
- Research Site - Round Rock
Arizona
- Research Site - Gilbert
Massachusetts
- Research Site - Boston
New Jersey
- Research Site - New Brunswick
New York
- Research Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-07-12 |
| Est. Completion | 2029-07-31 |
| Phase | Phase 1 |
What NCT05877599 shows while recruiting
NCT05877599 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Autologous, engineered T Cells targeting TP53 R175H is the first listed.
NCT05877599 lists 18 locations in 12 states (California, Florida, North Carolina).
Frequently Asked Questions
What is clinical trial NCT05877599 about?
NCT05877599 is a clinical study titled "A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation". Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
What is the current status of trial NCT05877599?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2023-07-12. Estimated completion is 2029-07-31.
What conditions does trial NCT05877599 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT05877599?
The interventions under investigation include: Autologous, engineered T Cells targeting TP53 R175H (BIOLOGICAL).
Who is sponsoring clinical trial NCT05877599?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05877599 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05877599's enrollment target sits among peer trials
46 835th of 1224 higher than 383 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI